Article summary
Welcome to our Q3 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug development, policy and regulation, science and academia, and much more. He closes with a look ahead to the next quarter, so you know what to look out for.
Continue to the original publication for the complete article.